Shalby Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book

Published 26 Aug 2026 | Healthcare Services | Market Cap: ₹1.7K Cr

Hospital business expected to grow at double-digit rates, maintaining 5-7 years’ growth trend. Hospital business expected to grow at double-digit rates for next 5-7 years due to unutilized capacity and ongoing expansions (Shanay Shah, Page 11).

From Shalby Ltd's Q4 FY25 earnings-call transcript · updated 26 Aug 2026.

Price

₹155

Market Cap

₹1.7K Cr

P/E Ratio

42.0

How does Shalby Ltd rank in Healthcare Services?

Compare Shalby Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Shalby Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹287 Cr, net profit ₹18 Cr.

Full financials →

📊 Revenue & Sales Performance

→Hospital business expected to grow at double-digit rates, maintaining 5-7 years’ growth trend.
→Sanar Hospital (newer business) anticipated to grow at higher double-digit rates until capacity is exhausted.
→Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year.
→Two new implant products planned to launch in FY '26, expected to add INR40-50 crores yearly revenue after regulatory approvals.
→Long-term implant product pipeline includes 5-6 products, given a roughly 3-year gestation period per product.
→Overall consolidated revenue for FY '26 expected to see high single-digit growth or better compared to FY '25.
→Capacity in hospital setups has room to double revenue without expansion; expansion projects (e.g., Mumbai hospital) underway but delayed.
→Focus on talent acquisition and super specialty verticals to drive future growth.

📈 Profitability & Margins

→Hospital business expected to grow at double-digit rates for next 5-7 years due to unutilized capacity and ongoing expansions (Shanay Shah, Page 11).
→Sanar Hospital poised for higher double-digit growth; revenue and patient counts increasing steadily, EBITDA expected to turn positive within the year (Page 10-11).
→Implant business is in high growth, having grown 4x in Indonesia, 35-40% in the US, and 2.5x in India; expected to maintain high double-digit growth trajectory driven by new product launches contributing INR40-50 crores annually (Page 11-13).
→Overall consolidated revenue for FY '26 expected to be better than FY '25, suggesting higher single-digit to double-digit growth (Amit Pathak, Page 15-16).
→Operating performance may improve as investments in talent and infrastructure mature; EBITDA impact due to investing phase expected to reverse (Page 9-10).
→Tax rate for FY '26 projected around 25% (Page 12).

See what Shalby Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Shalby is expanding capacity in ROCE-accretive businesses.
→Recent large acquisition of nearly INR 300 crores in last 15 months.
→Adding a hospital in Mumbai with an investment of over INR 250 crores.
→Sanar hospital optional bed expansion from 130 to 180 beds planned; timelines depend on occupancy and approvals.
→Franchisee business growing selectively with focus on quality partnerships; minimal capital employed but requires management bandwidth.
→Implant business investing significantly for growth; product development and regulatory approvals ongoing.
→Technology investments planned to accelerate growth, especially in home care business in future phases.
→Mumbai hospital project to commence post regulatory approvals and finalization of agreements; construction expected within 6-9 months once started.

💰 Fundraising & Capital Structure

→There is no explicit mention of current or future fundraising through debt or equity in the provided transcript excerpt.
→The company highlights a strong balance sheet with low gearing (0.2 net debt of around INR279 crores).
→Focus appears to be on internal cash flow and strategic investments, including acquisitions and expansions (e.g., INR300 crores acquisition, INR250 crores investment in Mumbai hospital).
→Dividend distribution is being reserved to maintain cash for ongoing investments.
→Management emphasizes growth through operational expansion and partnerships rather than raising external funds at this stage.

See what Shalby Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The transcript on page 15 of Shalby Limited's Q4 FY '25 earnings call does not provide a specific figure or detailed commentary on the current or expected order book or pending orders. Key points related to business growth and outlook include: - Hospital business expected to continue double-digit growth. - Implant business anticipated to grow at higher double-digit rates due to a lower base. - Implant segment grew approximately 50% on a 12-month consolidated basis in FY '25. - Launch of two new implant products planned, potentially contributing INR40-50 crores annually. - Expansion plans include launching operations in 4-5 new countries in '25-'26. - Ongoing focus on supply chain and cost efficiencies to improve margins and operational performance. No explicit update on order book or pending order backlog is mentioned in the provided transcript excerpt.

Key Metrics

What Shalby's management said in earlier quarters

Others in Healthcare Services this season

Apollo Hospitals Enterprise Ltd (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
Suraksha Diagnostic Ltd (Q4 FY25)
Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. Key concall takeaways from Suraksha Diagnostic Ltd's Q4 FY25…
Narayana Hrudaya (Q4 FY25)
Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…
Healthcare Global Enterprises Ltd (Q4 FY25)
FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores. Key concall takeaways from Healthcare Global Enterprises Ltd's Q4 FY25…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Fortis Health.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Shalby Ltd Q4 FY25 results?

What is Shalby Ltd share price analysis?

Shalby Ltd currently shows a neutral. The stock trades at a P/E of 42.0 with a market cap of ₹1,652 Cr. Investors should review the full earnings analysis for detailed insights.

Is Shalby Ltd planning capital expenditure?

Shalby is expanding capacity in ROCE-accretive businesses.

Keep Shalby Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.